A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer
The mortality rate in patients suffering from non-small cell lung cancer (NSCLC) is quite high. This type of cancer mainly occurs due to rearrangements in the anaplastic lymphoma kinase (ALK) gene which leads to form an oncogene of fused gene NPM-ALK. Brigatinib is recently approved by FDA in April...
Main Authors: | Silky Bedi, Shah A. Khan, Majed M. AbuKhader, Perwez Alam, Nasir A. Siddiqui, Asif Husain |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-09-01
|
Series: | Saudi Pharmaceutical Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016418300902 |
Similar Items
-
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
by: Mezquita L, et al.
Published: (2018-01-01) -
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
by: Sabari JK, et al.
Published: (2017-04-01) -
Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
by: Ali R, et al.
Published: (2019-02-01) -
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
by: Ken Uchibori, et al.
Published: (2017-03-01) -
Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies
by: Bo Li, et al.
Published: (2019-01-01)